CPI-0610 - CAS 1380087-89-7
Catalog number: 1380087-89-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H16ClN3O2
Molecular Weight:
365.81
COA:
Inquire
Targets:
BET Bromodomain
Description:
CPI-0610, a benzazepine derivative, has been found to influence tumor cell growth at some extent by acting as a BET bromodomain inhibitor. IC50: < 500 nM for BRD4. It is still under a Phase I trial for Leukaemia, Lymphoma and sorts of other cancers.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
2-[6-(4-Chloro-phenyl)-1-methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetamide
Solubility:
10 mM in DMSO
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
CPI-0610 has been found to influence tumor cell growth at some extent by acting as a BET bromodomain inhibitor.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Milligrams-Grams
InChIKey:
GCWIQUVXWZWCLE-UHFFFAOYSA-N
InChI:
InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)
Canonical SMILES:
CC1=NOC2=C1C3=CC=CC=C3C(=NC2CC(=O)N)C4=CC=C(C=C4)Cl
Current Developer:
Constellation Pharmaceuticals; The Leukemia & Lymphoma Society
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related BET Bromodomain Products


CAS 1370888-71-3 XD 14

XD 14
(CAS: 1370888-71-3)

XD 14 is a BET bromodomain inhibitor (Kd = 160, 170, 380, 490, 830 and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2) respectively). XD 14 a...

CAS 1883545-47-8 I-BET 151 dihydrochloride

I-BET 151 dihydrochloride
(CAS: 1883545-47-8)

The hydrochloride salt form of I-BET 151, which has been found to be a BET bromodomain inhibitor and exhibit activities against human and murine MLL-fusion leuk...

ISOX INACT

ISOX INACT is an inactive control probe of the bromodomain of CREB binding protein (CBP) PF-CBP1. It shows negligible activity at CBP and BRD4. It was used to p...

CAS 202590-98-5 OTX015

OTX015
(CAS: 202590-98-5)

OTX015 a potent BET bromodomian inhibitor, which targets the BET bromodomain proteins 2, 3, and 4 (BRD). BRDs 2, 3, and 4 are considered potential cancer target...

PFI-4
(CAS: 900305-37-5)

PFI-4 is a potent and selective BRPF1 bromodomain inhibitor with IC50 of 80 nM.

CAS 1395084-25-9 MS436

MS436
(CAS: 1395084-25-9)

MS436 exhibits low nanomolar affinity with preference for the first bromodomain over the second.

CPI-0610
(CAS: 1380087-89-7)

CPI-0610, a benzazepine derivative, has been found to influence tumor cell growth at some extent by acting as a BET bromodomain inhibitor. IC50: < 500 nM for BR...

CAS 2018300-62-2 TPOP146

TPOP146
(CAS: 2018300-62-2)

TPOP146 is a potent and selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4. TPOP146 targets the CBP br...

CAS 1869912-40-2 AZD5153 6-Hydroxy-2-naphthoic acid

AZD5153 6-Hydroxy-2-naphthoic acid
(CAS: 1869912-40-2)

AZD5153 6-Hydroxy-2-naphthoic acid, a 6-hydroxy-2-naphthoic acid salt of AZD-5153, is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor p...

Mivebresib
(CAS: 1445993-26-9)

Mivebresib is a BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce po...

Olinone
(CAS: 1770789-37-1)

Olinone, a pyridoindol derivative, has been found to be an BET Bromodomain inhibitor and could be probably useful in sorts of biological studies.

LP99
(CAS: 1808951-93-0)

LP99 is the first selective BRD7/9 bromodomain inhibitor. The effect of LP99 on IL-6 expression demonstrates for the first time that a small-molecule BRD7/9 in...

BET bromodomain inhibitor
(CAS: 1505453-59-7)

An BET bromodomain inhibitor can be used for the treatment of hematologic malignancies. It binds BET proteins to suppress the interaction between these proteins...

BET-BAY 002
(CAS: 1588521-78-1)

BET-BAY 002 is a potent BET inhibitor with strong in vitro and in vivo activities in AML and MM models, and with excellent pharmacokinetic properties.

CAS 755038-02-9 BI-2536

BI-2536
(CAS: 755038-02-9)

BI-2563 is a small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arr...

CAS 1300031-49-5 I-BET151

I-BET151
(CAS: 1300031-49-5)

I-BET151, also known as GSK1210151A, is a BET bromodomain inhibitor, which blocks recruitment of BET to chromatin. I-BET151 (GSK1210151A) shows good oral bioava...

CAS 1429129-68-9 OXF BD 02

OXF BD 02
(CAS: 1429129-68-9)

OXF BD 02 is a first bromodomain of BRD4 inhibitor with IC50 value of 382 nM. It can reduce viability of lung adenocarcinoma cell lines and attenuate proliferat...

CAS 1268524-71-5 (R)-(-)-JQ1

(R)-(-)-JQ1
(CAS: 1268524-71-5)

The (R) - isomer form of JQ1 which is a BET inhibitor that could probably influence the inflammatory expression at some extent.

CAS 1962928-21-7 PF-CBP1

PF-CBP1
(CAS: 1962928-21-7)

PF-CBP1, also known as PF-06670910, is a selective CBP/p300 bromodomain inhibitor (IC50 values are 125 and 363 nM, respectively) with >100-fold selectivity for ...

CAS 1300031-52-0 GSK1324726A (I-BET726)

GSK1324726A (I-BET726)
(CAS: 1300031-52-0)

GSK1324726A (I-BET726) is a novel, potent, and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50= 41 nM), BRD3 (IC50= 31 nM), ...

Quick Inquiry

Verification code

Featured Items